I take no blood pressure medication at all. Can I still get dizzy standing up?

Yes. Eating less brings in less water and less salt, and the labelled dehydration pathway after nausea or diarrhoea does not care whether you take an antihypertensive. Medication overshoot is the most common explanation for it, not the only one. The reporting threshold is the same for you: light-headedness at the next opportunity, fainting or nearly fainting as a prompt call.

The label says 1 to 4 bpm. My watch is showing a bigger jump than that.

That figure is a group mean from the Wegovy label rather than a ceiling for one person. A single reading is also a weak thing to hold up against a trial average, so readings taken the same way over a fortnight are what a prescriber can actually work with. A sustained rise or palpitations is something the label directs you to report, whatever the number turns out to be.

If my readings settle and my dose comes down, is that permanent?

It holds for as long as the weight does. A dose set for a lighter body can be wrong again if weight returns, which is the situation our page on stopping and weight regain deals with. Changes in either direction are your prescriber's to make, and they make them on readings rather than on how you feel.

GLP-1 and Blood Pressure

What this page establishes

Weight reduction with GLP-1 therapy lowers blood pressure, and reduction in adiposity measures mediated a substantial share of the cardiovascular benefit in SELECT.
Semaglutide reduced major adverse cardiovascular events by 20% in SELECT despite the documented small rise in resting heart rate.
Resting heart rate rises a mean of 1 to 4 bpm on semaglutide per the Wegovy label, in the opposite direction to blood pressure.
The ADA obesity chapter addresses weight-loss pharmacotherapy alongside cardiometabolic risk-factor management including blood pressure.

Quick answers

I take no blood pressure medication at all. Can I still get dizzy standing up?
Yes. Eating less brings in less water and less salt, and the labelled dehydration pathway after nausea or diarrhoea does not care whether you take an antihypertensive.
Read the full answer
Medication overshoot is the most common explanation for it, not the only one. The reporting threshold is the same for you: light-headedness at the next opportunity, fainting or nearly fainting as a prompt call.
The label says 1 to 4 bpm. My watch is showing a bigger jump than that.
That figure is a group mean from the Wegovy label rather than a ceiling for one person. A single reading is also a weak thing to hold up against a trial average, so readings taken the same way over a fortnight are what a prescriber can…
Read the full answer
That figure is a group mean from the Wegovy label rather than a ceiling for one person. A single reading is also a weak thing to hold up against a trial average, so readings taken the same way over a fortnight are what a prescriber can actually work with. A sustained rise or palpitations is something the label directs you to report, whatever the number turns out to be.
If my readings settle and my dose comes down, is that permanent?
It holds for as long as the weight does. A dose set for a lighter body can be wrong again if weight returns, which is the situation our page on stopping and weight regain deals with.
Read the full answer
Changes in either direction are your prescriber's to make, and they make them on readings rather than on how you feel.

Blood pressure generally falls on a GLP-1, driven mostly by the weight loss rather than by anything exotic. Resting heart rate goes the other way, rising a mean of 1 to 4 bpm on semaglutide according to the Wegovy label. Those two facts together confuse a lot of people, and they are not a contradiction: different mechanisms, different directions. The practical consequence is more useful than the physiology. If you take blood pressure medication at a dose set for your pre-treatment body, that dose can become too strong as weight falls, and dizziness on standing is usually the first sign. Adjusting it is your prescriber's job, and giving them home readings to work from makes that easier.

What happens to blood pressure

Weight reduction with GLP-1 therapy lowers blood pressure. In SELECT, reduction in adiposity measures mediated a substantial share of the cardiovascular benefit, with roughly a third of the benefit mediated through waist-circumference reduction, which tells you how much of the cardiovascular story runs through body composition rather than through a direct drug effect on the vessels.

The size of the fall tracks the size of the weight loss, broadly. Someone who loses 15% of body weight sees more movement than someone who loses 4%, and the change is gradual rather than sudden.

That gradual quality is part of why it catches people out. Nobody notices the day their pressure crossed below the range their medication was set for. What they notice, weeks later, is standing up from a chair and having to wait a moment before walking. The ADA obesity chapter treats weight-loss pharmacotherapy and cardiometabolic risk-factor management as one problem rather than two, and blood pressure is the clearest example of why.

Why pressure falls while heart rate rises

Blood pressure falls through several converging routes. Circulating volume drops. Sympathetic nervous system drive decreases as visceral fat reduces. Insulin sensitivity improves, so the kidney retains less sodium. Endothelial function gets better. All of these push pressure down.

Heart rate moves the other way for an unrelated reason. GLP-1 receptor activation has a direct positive chronotropic effect at the sinoatrial node, the heart's own pacemaker. That is a drug effect on the heart itself rather than a consequence of the weight change.

The result is a slightly faster circulation running at lower pressure. Our page on heart rate covers the rate side in detail, including the label's instruction to monitor heart rate and to report palpitations.

This pattern is expected A home monitor showing lower pressure and a higher pulse than you are used to is the documented pattern on this drug class, not a machine error and not a contradiction. Persistent palpitations or a sustained large rise in resting heart rate is a different matter and should be reported.

Antihypertensive doses set for a heavier body

This is the part with real consequences. Blood pressure medication doses are titrated against readings taken at the time. Lose 15% of your body weight over a year and the same doses act on a system that no longer needs as much help.

Overshoot produces symptomatic hypotension: dizziness or light-headedness on standing, occasionally fainting, sometimes just a persistent washed-out feeling. It is common enough during substantial weight loss that it should be anticipated rather than treated as a surprise.

Reducing or stopping an antihypertensive is a prescriber decision and it needs data. Do not adjust the dose yourself, and do not stop a medication because a single reading looked low.

Bring readings, not impressions A prescriber can act on a fortnight of home readings taken at consistent times. They cannot act on a general sense that your readings seem lower. If you are losing weight steadily and take blood pressure treatment, keeping a simple log during titration gives them something to work with.

Dehydration makes it worse

FDA labelling for this class warns about dehydration following gastrointestinal adverse reactions, and the same volume loss that threatens the kidneys also drops blood pressure further.

So the worst combination is a week of nausea or diarrhoea, reduced fluid intake, and unchanged antihypertensive doses. That is when dizziness on standing tips into fainting. If you are unwell with GI symptoms, our page on sick-day planning covers what the labels say about that pathway.

Reduced food intake on this drug class also means reduced dietary sodium and reduced dietary water, both of which nudge pressure down over time even without an acute illness.

The net cardiovascular picture

It is reasonable to ask whether a small persistent rise in heart rate offsets the benefits. SELECT answers that directly. In 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20%.

That result was obtained in the same drug, at the same dose, that carries the documented 1 to 4 bpm heart rate rise. The rise was known and measured, and the outcome trial still showed a 20% reduction in events. The label's monitoring instruction stands, and so does that result.

Home monitoring during titration

If you take antihypertensive medication, monitoring at home through the titration period and through any phase of rapid weight loss gives your prescriber the information they need to act at the right time.

Take readings at consistent times, seated and rested, and write them down alongside the date. A pattern over two weeks is far more useful than a handful of readings taken when you happened to feel odd. Note any dizziness on standing next to the readings, since symptoms and numbers do not always move together.

Ask your prescriber what range they want to see and at what point they want to hear from you. That turns a vague instruction to monitor into something with a decision attached.

When to contact a clinician

Dizziness or light-headedness on standing, particularly if it is new or worsening
Fainting or near-fainting, which warrants prompt contact rather than a routine appointment
Home readings persistently below your usual range while still on full antihypertensive doses
Blurred vision, confusion or marked weakness
Hypotension symptoms alongside vomiting or diarrhoea, where dehydration is compounding the drop
A sustained rise in resting heart rate, or palpitations, which the label directs you to report

Fainting is not something to monitor at home Light-headedness on standing is worth reporting at the next opportunity. Actually fainting, or nearly doing so, warrants contacting a clinician promptly, especially if you take blood pressure medication or have had recent vomiting or diarrhoea.

Not medical advice

This page reports what prescribing information and published trials describe. It is general educational information, not advice about your medication. Never change or stop an antihypertensive on the basis of what you read here.

The evidence, one row per claim

Claim	Tier	Source
Weight reduction with GLP-1 therapy lowers blood pressure, and reduction in adiposity measures mediated a substantial share of the cardiovascular benefit in SELECT.	established	Semaglutide and cardiovascular outcomes by adiposity measurements, The Lancet
Semaglutide reduced major adverse cardiovascular events by 20% in SELECT despite the documented small rise in resting heart rate.	established	SELECT trial summary, ACC
Resting heart rate rises a mean of 1 to 4 bpm on semaglutide per the Wegovy label, in the opposite direction to blood pressure.	established	WEGOVY US Prescribing Information, FDA
The ADA obesity chapter addresses weight-loss pharmacotherapy alongside cardiometabolic risk-factor management including blood pressure.	established	ADA Standards of Care 2026, Section 8
Dehydration from GI adverse reactions can lower blood pressure further and is a labelled concern on this class.	established	OZEMPIC US Prescribing Information, FDA

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 5 sourced claims below the fold, each with the document it came from.

Sources consulted: Semaglutide and cardiovascular outcomes by adiposity measurements, SELECT trial summary, WEGOVY US Prescribing Information, ADA Standards of Care 2026, OZEMPIC US Prescribing Information.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.